| APS-1 | Autoimmune Polyendocrine Syndrome Type 1 |
| APECED | Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy |
| AIRE | Autoimmune Regulator |
| CMC | Chronic Mucocutaneous Candidiasis |
| SCC | Squamous Cell Carcinoma |
| HNSCC | Head and Neck Squamous Cell Carcinoma |
| IL | Interleukin |
| IFN | Interferon |
| EGFR | Epidermal Growth Factor Receptor |
| MAPK | Mitogen-Activated Protein Kinase |
| NF-κB | Nuclear Factor Kappa-light-chain-enhancer of activated B cells |
| STAT3 | Signal Transducer and Activator of Transcription 3 |
| TP53 | Tumor Protein p53 |
| CDKN2A | Cyclin Dependent Kinase Inhibitor 2A (p16INK4a) |
| PICOS | Population, Intervention, Comparator, Outcome, Study Design |
| PRISMA-ScR | Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Re-views |
| ROB | Risk of Bias |
| ROS | Reactive Oxygen Species |
| RNS | Reactive Nitrogen Species |
| OLP | Oral Lichen Planus |
| SEER | Surveillance, Epidemiology, and End Results Program |